Results 1 to 10 of about 54,122 (123)

Factors affecting two-point discrimination in Argus II patients. [PDF]

Front Neurosci, 2022
Two of the main obstacles to the development of epiretinal prosthesis technology are electrodes that require current amplitudes above safety limits to reliably elicit percepts, and a failure to consistently elicit pattern vision. Here, we explored the causes of high current amplitude thresholds and poor spatial resolution within the Argus II epiretinal
Yücel EI, Sadeghi R, Kartha A, Montezuma SR, Dagnelie G, Rokem A, Boynton GM, Fine I, Beyeler M.   +8 more
europepmc   +6 more sources

A Patient-Specific Computational Framework for the Argus II Implant. [PDF]

IEEE Open J Eng Med Biol, 2020
Retinal prosthesis performance is limited by the variability of elicited phosphenes. The stimulating electrode's position with respect to retinal ganglion cells (RGCs) affects both perceptual threshold and phosphene shape. We created a modeling framework incorporating patient-specific anatomy and electrode location to investigate RGC activation and ...
Finn KE, Zander HJ, Graham RD, Lempka SF, Weiland JD.   +4 more
europepmc   +5 more sources

Hemifacial Spasm in an Argus II Retinal Prosthesis Patient. [PDF]

J Vitreoretin Dis, 2020
Purpose: A 59-year-old man with retinitis pigmentosa, who received an Argus II retinal prosthesis in the left eye 3 years prior, presented with left-sided involuntary facial contractions that occurred only after turning on the Argus II device. Methods: A case report.
Sun SY, Mammo DA, Koozekanani DD, Montezuma SR.   +3 more
europepmc   +3 more sources

Long term positional stability of the Argus II retinal prosthesis epiretinal implant. [PDF]

BMC Ophthalmol, 2023
Abstract Background The Argus II Retinal Prosthesis System (Second Sight Medical Products, Sylmar, California) is an epiretinal prosthesis that serves to provide useful vision to people who are affected by retinal degenerative diseases such as retinitis pigmentosa (RP).
Ghani N, Bansal J, Naidu A, Chaudhary KM.   +3 more
europepmc   +4 more sources

Worldwide Argus II implantation: recommendations to optimize patient outcomes. [PDF]

BMC Ophthalmol, 2016
BMC ophthalmology 16(1), 52 (2016).
Ghodasra DH, Chen A, Arevalo JF, Birch DG, Branham K, Coley B, Dagnelie G, de Juan E, Devenyi RG, Dorn JD, Fisher A, Geruschat DR, Gregori NZ, Greenberg RJ, Hahn P, Ho AC, Howson A, Huang SS, Iezzi R, Khan N, Lam BL, Lim JI, Locke KG, Markowitz M, Ripley AM, Rankin M, Schimitzek H, Tripp F, Weiland JD, Yan J, Zacks DN, Jayasundera KT.   +31 more
europepmc   +6 more sources

Phthisis Bulbi in a Retinitis Pigmentosa Patient after Argus II Implantation. [PDF]

Case Rep Ophthalmol Med, 2020
Purpose. To report a previously unreported complication of phthisis after Argus II prosthesis implantation in a retinitis pigmentosa (RP) patient. Case. A 61-year-old male with advanced RP presented to the retina clinic. The patient had a history of vitrectomy in both eyes (OU) in Cuba in 1996. Pre-op visual acuity (VA) was no light perception (NLP) in
Woude LV, Roohipour R, Khurshid GS.
europepmc   +5 more sources

Intraoperative OCT Imaging of the Argus II Retinal Prosthesis System. [PDF]

Ophthalmic Surg Lasers Imaging Retina, 2016
BACKGROUND AND OBJECTIVE: Optimal placement of the Argus II Retinal Prosthesis System (Second Sight Medical Products, Sylmar, CA) is critical. Intraoperative optical coherence tomography (OCT) allows for intrasurgical visualization and confirmation of array placement.
Rachitskaya AV, Yuan A, Marino MJ, Reese J, Ehlers JP.   +4 more
europepmc   +4 more sources

The functional performance of the Argus II retinal prosthesis. [PDF]

Expert Rev Med Devices, 2014
Visual prostheses are devices to treat profound vision loss by stimulating nerve cells anywhere along the visual pathway, typically with electrical pulses. The Argus II implant, developed by Second Sight Medical Products (SSMP, Sylmar, CA, USA), targets the retina and features 60 electrodes that electrically stimulate the surviving retinal neurons.
Stronks HC, Dagnelie G.
europepmc   +4 more sources

The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients. [PDF]

BMC Ophthalmol, 2014
This is the final version of the article. Available from the publisher via the DOI in this record.BACKGROUND: Retinitis Pigmentosa (RP) is a hereditary genetic disease causing bilateral retinal degeneration.
Vaidya A, Borgonovi E, Taylor RS, Sahel JA, Rizzo S, Stanga PE, Kukreja A, Walter P.   +7 more
europepmc   +2 more sources

Visual BOLD Response in Late Blind Subjects with Argus II Retinal Prosthesis. [PDF]

PLoS Biol, 2016
Retinal prosthesis technologies require that the visual system downstream of the retinal circuitry be capable of transmitting and elaborating visual signals. We studied the capability of plastic remodeling in late blind subjects implanted with the Argus II Retinal Prosthesis with psychophysics and functional MRI (fMRI).
Castaldi E, Cicchini GM, Cinelli L, Biagi L, Rizzo S, Morrone MC.   +5 more
europepmc   +8 more sources